Bristol-Myers Squibb Company (BMY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bristol-Myers Squibb Company (BMY) has a cash flow conversion efficiency ratio of 0.055x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.10 Billion) by net assets ($20.10 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bristol-Myers Squibb Company (BMY) net asset quality to measure how much of total assets are equity-financed.
Bristol-Myers Squibb Company - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Bristol-Myers Squibb Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Bristol-Myers Squibb Company cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Bristol-Myers Squibb Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bristol-Myers Squibb Company ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Banco Bilbao Vizcaya Argentaria SA
MC:BBVA
|
0.278x |
|
Safran SA
PA:SAF
|
0.200x |
|
China Life Insurance Co Ltd A
SHG:601628
|
0.194x |
|
Starbucks Corporation
NASDAQ:SBUX
|
-0.043x |
|
ServiceNow Inc
NYSE:NOW
|
0.173x |
|
Altria Group
NYSE:MO
|
-0.948x |
|
UNICREDIT S.P.A. ADR
F:CRIP
|
N/A |
|
BP p.l.c
MX:BPN
|
0.037x |
Annual Cash Flow Conversion Efficiency for Bristol-Myers Squibb Company (1989–2025)
The table below shows the annual cash flow conversion efficiency of Bristol-Myers Squibb Company from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see Bristol-Myers Squibb Company (BMY) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.51 Billion | $14.16 Billion | 0.765x | -17.47% |
| 2024-12-31 | $16.39 Billion | $15.19 Billion | 0.927x | +97.18% |
| 2023-12-31 | $29.48 Billion | $13.86 Billion | 0.470x | +11.95% |
| 2022-12-31 | $31.12 Billion | $13.07 Billion | 0.420x | -6.72% |
| 2021-12-31 | $36.01 Billion | $16.21 Billion | 0.450x | +21.35% |
| 2020-12-31 | $37.88 Billion | $14.05 Billion | 0.371x | +137.72% |
| 2019-12-31 | $51.70 Billion | $8.07 Billion | 0.156x | -68.80% |
| 2018-12-31 | $14.13 Billion | $7.07 Billion | 0.500x | +12.33% |
| 2017-12-31 | $11.85 Billion | $5.28 Billion | 0.445x | +138.02% |
| 2016-12-31 | $16.35 Billion | $3.06 Billion | 0.187x | +28.18% |
| 2015-12-31 | $14.42 Billion | $2.10 Billion | 0.146x | -30.54% |
| 2014-12-31 | $14.98 Billion | $3.15 Billion | 0.210x | -9.70% |
| 2013-12-31 | $15.24 Billion | $3.54 Billion | 0.233x | -54.28% |
| 2012-12-31 | $13.64 Billion | $6.94 Billion | 0.509x | +66.85% |
| 2011-12-31 | $15.87 Billion | $4.84 Billion | 0.305x | +6.22% |
| 2010-12-31 | $15.64 Billion | $4.49 Billion | 0.287x | +4.45% |
| 2009-12-31 | $14.79 Billion | $4.07 Billion | 0.275x | -9.46% |
| 2008-12-31 | $12.21 Billion | $3.71 Billion | 0.304x | +1.72% |
| 2007-12-31 | $10.56 Billion | $3.15 Billion | 0.299x | +43.18% |
| 2006-12-31 | $9.99 Billion | $2.08 Billion | 0.208x | +27.27% |
| 2005-12-31 | $11.21 Billion | $1.84 Billion | 0.164x | -47.38% |
| 2004-12-31 | $10.20 Billion | $3.18 Billion | 0.311x | -13.25% |
| 2003-12-31 | $9.79 Billion | $3.51 Billion | 0.359x | +232.52% |
| 2002-12-31 | $8.76 Billion | $945.00 Million | 0.108x | -78.55% |
| 2001-12-31 | $10.74 Billion | $5.40 Billion | 0.503x | -0.71% |
| 2000-12-31 | $9.18 Billion | $4.65 Billion | 0.507x | +3.71% |
| 1999-12-31 | $8.64 Billion | $4.22 Billion | 0.489x | -2.12% |
| 1998-12-31 | $7.58 Billion | $3.78 Billion | 0.499x | +45.55% |
| 1997-12-31 | $7.22 Billion | $2.48 Billion | 0.343x | -14.68% |
| 1996-12-31 | $6.57 Billion | $2.64 Billion | 0.402x | -6.35% |
| 1995-12-31 | $5.82 Billion | $2.50 Billion | 0.429x | +6.40% |
| 1994-12-31 | $5.70 Billion | $2.30 Billion | 0.403x | -7.12% |
| 1993-12-31 | $5.94 Billion | $2.58 Billion | 0.434x | +28.93% |
| 1992-12-31 | $6.02 Billion | $2.03 Billion | 0.337x | +6.39% |
| 1991-12-31 | $5.79 Billion | $1.83 Billion | 0.317x | -2.08% |
| 1990-12-31 | $5.42 Billion | $1.75 Billion | 0.323x | +38.15% |
| 1989-12-31 | $5.08 Billion | $1.19 Billion | 0.234x | -- |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for… Read more